Abstract RF6-06: Patient-reported outcomes (PROs) in DESTINY-Breast11: neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) alone or followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (ddAC-THP) in high-risk, HER2+ early-stage breast cancer (eBC)

作者：S. Modi, J. Boileau, J. Wu, L. Pusztai, Shinji Ohno, G. Curigliano, C. Kelly, Jamil Asselah, S. Im, L. Coltelli, Mukesh Chaudhari, Sibel Blau, A. Martínez Bueno, B. Czartoryska-Arlukowicz, José Luiz Pedrini, Chi Zhang, S. Safdar, S. Mannix, N. Harbeck · 发表于：Clinical Cancer Research · 年份：2026 · DOI：10.1158/1557-3265.sabcs25-rf6-06 · 研究领域：Breast Cancer Treatment Studies、Advanced Breast Cancer Therapies、Cancer Risks and Factors

Abstract Background: In the DESTINY-Breast11 Phase 3 study, NAT with T-DXd-THP showed a statistically significant and clinically meaningful improvement in pathologic complete response rate and improved safety profile vs ddAC-THP in high-risk, HER2+ eBC. We report physical functioning (PF) and patient-reported tolerability during NAT. Methods: Patients with high-risk (≥T3, node positive [N1-3], or inflammatory), HER2+ eBC were randomized to NAT T-DXd (8 cycles), T-DXd-THP (4+4 cycles), or ddAC-THP (4+4 cycles). PF was measured on the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire Core 30 (QLQ-C30) PF subscale. Twenty symptomatic adverse events (AEs) were measured using select items from the PRO version of the Common Terminology Criteria for Adverse Events, EORTC-QLQ-C30, and EORTC item library. The Patient Global Impression of Treatment Tolerability measured overall side-effect bother. Descriptive PRO analyses included all patients who received ≥1 dose of study intervention. Results: In the T-DXd, T-DXd-THP, and ddAC-THP arms, respectively, 283, 320, and 312 patients began treatment. More patients had maintained or improved PF during NAT with T-DXd and T-DXd-THP vs ddAC-THP (range across weeks, respectively: 42.7-75.5%, 43.7-75.7%, and 24.0-62.4%; Table). Overall side-effect bother during NAT was generally lower with T-DXd and T-DXd-THP than ddAC-THP, with a numerically lower proportion of patient-weeks with high side-effect bo...